GE Healthcare, CCRM, Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, CIRM, SENS Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, NYSCF, ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche, Oxford Biomedica, Oxford NIHR BRU, the Saïd Foundation, the SENS Research Foundation, Innovate UK (formerly Technology Strategy Board).
DPhil MEng FRSA
Senior Research Fellow in Healthcare Translation
- Adjunct Research Fellow: Harvard Stem Cell Institute; University College London, Centre for Behavioural Medicine; Stanford-UCSF FDA Centre for Regulatory Innovation and Science
- Industrial Engagement: Managing Partner, IP Asset Ventures; Chief Scientific Officer, Aegate Ltd
Accelerating the translation of healthcare innovations from scientific ideas into commercially viable and efficacious patient outcomes
Dr David Brindley is an international research and industrial leader in healthcare translation. Specifically, at the intersection of novel therapeutic platforms and supporting their efficacious and rapid deployment utilising e-health technologies.
David’s research group has a track record of delivering high-impact research in regenerative medicine (cell, gene, immuno-therapies and tissue engineering) and e-health – including medicines optimisation and supply chain security. This is complemented by research into critical enabling infrastructure including novel regulatory pathways, clinical adoption, biomanufacturing, reimbursement and intellectual property. Research outputs are published regularly in high impact journals including Nature, Cell Stem Cell and Nature Biotechnology.
Presently, David is a Senior Research Fellow in Healthcare Translation in the University of Oxford’s Department of Paediatrics, and directs the the Healthcare Innovation and Entrepreneurship MBA elective at the Saïd Business School. This is complemented by secondary research activities at the Harvard Stem Cell Institute, Harvard Business School, University College London, the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovations (CASMI) the Stanford-USCF FDA Centre for Regulatory Innovation and Science.
In order to maximise the commercial and patient impact of his research, David divides his time synergistically between academia and industry. David’s industrial positions include Chief Scientific Officer of Aegate Ltd and Managing Partner of IP Asset Ventures. In addition, David is a trusted advisor to major biopharmaceutical companies, life science venture capital funds and international regulators.
David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honours (Prof Chris Mason and Dr Ivan Wall), his Masters jointly at the Harvard Stem Cell Institute and Harvard Business School (Mr Brock Reeve and Prof William Sahlman), and his DPhil (PhD) in the risk:benefit appraisal of healthcare innovations at the University of Oxford (Worcester College, Prof Sir John Bell and Prof Andrew Carr). Post-Doctoral experience includes tenure as the Cooksey-Botnar-Saïd Fellow, the first joint post between the University of Oxford’s Medical Sciences Division and Saïd Business School.
The global intellectual property landscape of induced pluripotent stem cell technologies
Roberts M. et al, (2014), Nature Biotechnology, 32, 742 - 748
Establishing good authentication practice (GAP) in secondary care to protect against falsified medicines and improve patient safety.
Naughton BD. et al, (2016), European journal of hospital pharmacy. Science and practice, 23, 118 - 120
Health care: Better drug access for terminal patients.
Brindley DA. et al, (2013), Nature, 502
Establish good genomic practice to guide medicine forward.
Barker RW. et al, (2013), Nat Med, 19
Pharmaceutical industry: Investors unfazed by drug-patent expiry
Brindley D. et al, (2012), Nature, 481, 265 - 265
Evidence of insufficient quality of reporting in patent landscapes in the life sciences
Brindley DB. et al, (2017), Nature Biotechnology
Conditional Approval Pathways: The "Special" Case of Global Regenerative Medicine Regulation.
Smith JA. and Brindley DA., (2017), Rejuvenation Res, 20, 1 - 3
An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.
Meier A. et al, (2016), Clin Pharmacol Ther, 100, 743 - 753
The European Falsified Medicines Directive in Poland: background, implementation and potential recommendations for pharmacists
Merks P. et al, (2016), European Journal of Hospital Pharmacy, ejhpharm-2016-000970 - ejhpharm-2016-000970
EU Falsified Medicines Directive mandatory requirements for secondary care: A concise review
Naughton BD. et al, (2016), Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector